“Madopar” ( Madopar ) is a patented combination drug with the composition of levodopa + benserazide ( INN ).
General Information
Madopar is a combination drug containing L-DOPA and benserazide, an inhibitor of L-DOPA in the blood and peripheral organs similar in action to carbidopa .
Benserazide, or serazide, is N- (DL-seryl) -N- (2,3,4-trioxybenzyl) -hydrazine (hydrochloride).
Madopar is available in capsules containing respectively 50 mg of levodopa with 12.5 mg of benserazide (Madopar 62.5); 100 mg of levodopa and 25 mg of benserazide (madopar-125) and 200 mg of levodopa with 50 mg of benserazide (madopar-250).
Indications for use are the same as for Nacom .
Begin treatment with the admission of 1 capsule Madopar-125 3 times a day for one week. Then at intervals of one week, increase the dose by 1 capsule to achieve the optimal effect. The therapeutic dose is usually 4-8 capsules (rarely 10 capsules of Madopar-125) per day (in 3-4 doses). If the daily dose exceeds 5 capsules madopar-125, you can apply madopar-250 from the appropriate calculation.
The average dose for maintenance therapy is usually 1 capsule Madopar-250 3 times a day.
Madopar-62.5 capsules are designed for more accurate dose control in cases where it is necessary to reduce the dose or distribute the dose of Madopar-125 over 2 doses.
Contraindications
Possible side effects, precautions and contraindications are the same as when using nakoma.